EQ VS INDP Stock Comparison

Performance

EQ
10/100

EQ returned -70.89% in the last 12 months. Based on SPY's performance of -16.09%, its performance is below average giving it a score of 10 of 100.

INDP
100/100

INDP returned 20.93% in the last 12 months. Based on SPY's performance of -20.71%, its performance is above average giving it a score of 100 of 100.

Analyst Price Targets

EQ
100/100

2 analysts offer 12-month price targets for EQ. Together, they have an average target of 0, the most optimistic target put EQ at 0 within 12-months and the most pessimistic has EQ at 0.

INDP

"Analyst Price Targets" not found for INDP

Sentiment

EQ
72/100

EQ had a bullish sentiment score of 71.71% across Twitter and StockTwits over the last 12 months. It had an average of 4.25 posts, 3.92 comments, and 7.17 likes per day.

INDP
68/100

INDP had a bullish sentiment score of 68.36% across Twitter and StockTwits over the last 12 months. It had an average of 5.90 posts, 2.72 comments, and 6.97 likes per day.

Technicals

EQ
10/100

EQ receives a 10 of 100 based on 14 indicators. 0 are bullish, 12 are bearish.

INDP
11/100

INDP receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.

Earnings

EQ
10/100

EQ has missed earnings 8 times in the last 20 quarters.

INDP
10/100

INDP has missed earnings 10 times in the last 20 quarters.

Profit

EQ
10/100

Out of the last 20 quarters, EQ has had 1 profitable quarters and has increased their profits year over year on 1 of them.

INDP
15/100

Out of the last 13 quarters, INDP has had 2 profitable quarters and has increased their profits year over year on 1 of them.

Volatility

EQ
34/100

EQ has had a lower than average amount of volatility over the last 12 months giving it a score of 33 of 100.

INDP
46/100

INDP has had a lower than average amount of volatility over the last 12 months giving it a score of 45 of 100.

All score calculations are broken down here to help you make more informed investing decisions

Equillium, Inc. Common Stock Summary

Nasdaq / EQ

Healthcare

Biotechnology

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

Indaptus Therapeutics, Inc. Common Stock Summary

Nasdaq / INDP

Healthcare

Biotechnology

Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. was incorporated in 2021 and is headquartered in New York, New York.

Power up your portfolio